+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study

1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study

Drug Metabolism and Personalized Therapy 31(4): 205-212

Сytochrome P450 CYP2D6 activity affects antipsychotic therapy safety. 1846G>A (CYP2D6*4) polymorphism frequency varies among different ethnic groups. We studied 1846G>A polymorphism in Tatar and Russian schizophrenic patients taking different antipsychotics and association of 1846G>A polymorphism and extrapyramidal disorders (EPD) frequency in schizophrenic patients on haloperidol monotherapy in daily doses up to 20 mg. Heterozygous 1846GA genotype frequency among Tatars was lower (23.8% vs. 32.4% in Russians), but the differences did not reach statistical significance. The 1846A allele frequency among Tatars was also lower (11.9% vs. 24.3% in Russians), but the difference was not quite significant (p=0.0592). Average daily haloperidol dose in the group without EPD was significantly higher than in the group with EPD (11.35±4.6 vs. 13.87±3.3 mg, p=0.0252), but average daily haloperidol dose/weight ratios in the compared groups had no significant differences. A statistically significant association between EPD development and heterozygous 1846GA genotype and 1846A allele carrier frequency was revealed among all schizophrenic patients and among those of Tatars. Further well-designed pharmacogenetic studies in different Russian regions are needed to improve psychotropic therapy safety and to establish evidence-based indications for pharmacogenetic testing in clinical practice.

(PDF emailed within 0-6 h: $19.90)

Accession: 057010087

Download citation: RISBibTeXText

PMID: 27875318

DOI: 10.1515/dmpt-2016-0027

Related references

Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clinical and Experimental Pharmacology and Physiology 35(7): 807-811, 2008

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. European Journal of Clinical Pharmacology 56(9-10): 679-683, 2000

D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. International Clinical Psychopharmacology 12 Suppl 1: S3-S7, 1997

Association of the T174M Polymorphism of the Angiotensinogen Gene with Essential Hypertension in Russians and Tatars from Bashkortostan. Molecular Biology 36(4): 7-71, 2002

Brain neurotransmitter systems gene Polymorphism: the Search for pharmacogenetic markers of efficacy of haloperidol in Russians and Tatars. Molekuliarnaia Biologiia 49(6): 959-967, 2016

Association of CYP2D6 gene polymorphism and psychoactive drug therapy side effects. Clinical Chemistry & Laboratory Medicine 39(Special Supplement): S50, 2001

Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism. L'Encephale 26(1): 62-67, 2000

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. Journal of Psychopharmacology 20(6): 829-833, 2006

Glutamate receptors genes polymorphism and the risk of paranoid schizophrenia in Russians and tatars from the Republic of Bashkortostan. Molekuliarnaia Biologiia 48(5): 771-781, 2015

Polymorphism of the glutamate receptor genes and risk of paranoid schizophrenia in Russians and Tatars from the Republic of Bashkortostan. Molecular Biology 48(5): 671-680, 2014

Polymorphism of brain neurotransmitter system genes: Search for pharmacogenetic markers of haloperidol efficiency in Russians and Tatars. Molecular Biology 49(6): 858-866, 2015

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. European Journal of Clinical Pharmacology 55(9): 659-665, 1999

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 59(4): 222-226, 2009

Effect of estrogen pretreatment on neuropeptide gene expression following antipsychotic exposure in young and old female rats Differences and possible relevance to extrapyramidal motor side effects. Journal of Investigative Medicine 43(SUPPL 1): 117A, 1995

Extrapyramidal side effects of antipsychotic medications. American Journal of Nursing 81(7): 1324-1328, 1981